期刊文献+

TNFα在类风湿关节炎中的作用及抗TNFα药物的进展 被引量:3

The role of TNFoL in rheumatoid arthritis and progress of anti-TNFα agents
原文传递
导出
摘要 肿瘤坏死因子α(tumor necrosis factor alpha,TNFa)是一种具有多效生物活性的细胞因子,能够引起细胞凋亡、细胞增殖、分化、促炎症反应和免疫调节等作用。TNFα在类风湿关节炎(rheumatoid arthritis,RA)的致病机制中起关键作用。TNFa与TNF受体结合,能够引起细胞内的信号传导,通过复杂的级联反应和信号网络,激活转录因子核因子一KB(nuclearfactor—kappaB,NF—κB)和活化蛋白-1(acti—vatorprotein-1,AP.1),调控目的基因的表达,造成炎症反应和骨关节损伤。而以TNFct为靶位的药物已经被开发并应用于RA的临床治疗,通过阻断TNFα引起的信号传导来降低炎症反应被证明是安全有效的。此文就TNFα在RA病理机制中的作用及抗TNFα药物的进展作一综述。 Tumor necrosis factor alpha (TINFα) is a plelotroplc cytokme that mediates chverse biological effects, including apoptosis, cell proliferation, differentiation, proinflammatory reaction and immunoreg-lation. TiNFα is known to play a critical role in the pathogenic mechanism of rheumatoid arthritis (RA). Binding of TNFα to TNF receptor (TNFR) results in transduction of cellular signal. Through complex signaling cascades and networks, transcription factors NF-κB and AP-1 are activated to regulate target gene expression, resulting in joint inflammation and damage. Drugs targeting TNFα have been developed to reduce the injurious effects of proinflammatory cytokine and have proved to be safe and effective in the treatment of patients with RA. This article reviews the role of TNFα in pathogenic mechanism of RA and recent progress of anti- TNFα agents.
出处 《国际生物制品学杂志》 CAS 2010年第1期38-43,46,共7页 International Journal of Biologicals
关键词 肿瘤坏死因子Α 关节炎 类风湿 抗TNFα药物 Tumor necrosis factor-alpha Arthritis, rheumatoid Anti-TNFα agents
  • 相关文献

参考文献30

  • 1Baud V, Karin M. Signal transduction by tumor necrosis factor and its relatives [J]. Trends Cell Biol, 2001, 11 (9) :372-377.
  • 2Weaver AL. Differentiating the new rheumatoid arthritis biologic therapies [J]. J Clin Rheumatol, 2003, 9(2): 99-114.
  • 3Caporali R, Pallavicini FB, Filippini M, et al. Treatment of rheumatoid arthritis with anti-TNF-alpha agents: a reappraisal [J]. Autoimmun Rev, 2009, 8(3) : 274-280.
  • 4Goetz FW, Planas JV, MacKenzie S, et al. Tumor necrosis factors [J]. Dev Comp Immunol, 2004, 28(5) : 487-497.
  • 5Pfeffer K. Biological functions of tumor necrosis factor cytokines and their receptors [ J]. Cytokine Growth Factor Rev, 2003, 14 (3/4) : 185-191.
  • 6Bodmer JL, Schneider P, Tschopp J. The molecular architecture of the TNF superfamily [J]. Trends Biochem Sci, 2002, 27 (1): 19-26.
  • 7Zhang G. Tumor necrosis factor family ligand-receptor binding [J]. Curr Ooin Struct Biol, 2004, 14(2) : 154-160.
  • 8Russo C, Polosa R. TNF-alpha as a promising therapeutic target in chronic asthma: a lesson from rheumatoid arthritis [ J ]. Clin Sci, 2005, 109(2) : 135-142.
  • 9Aggarwal BB. Signalling pathways of the TNF superfamily: a double-edged sword [ J ]. Nat Rev Immunol, 2003, 3 ( 9 ) : 745-756.
  • 10Waldburger JM, Firestein GS. Signaling pathways in rheumatoid arthritis 2009 [ M ]//Tak PP. New therapeutic targets in rheumatoid arthritis. Basel : Birkhauser, 2009 : 155-150.

同被引文献53

  • 1黄少慧,李娟,赵毅,张娟.补肾中药骨灵片对人成骨细胞功能和p38活化原蛋白激酶通路的影响[J].热带医学杂志,2007,7(5):418-420. 被引量:16
  • 2Xiang Y J, Dai S M. Prevalence of rheumatic diseases and disability in China [J]. Rheumatol Int, 2009, 29(5): 481-490.
  • 3Barker T L, Puckert T L. Rheumatoid arthritis: coping with disability [J]. Rehabil Nurs, 2010, 35(2): 75-79.
  • 4Choy E H, Panayi G S. Cytokine pathways and joint inflammation in rheumatoid arthrltis[J].N Engl J Med, 2001, 344(12): 907-916.
  • 5Decks E D. Certolizumab pegol : a review of its use in the management of rheumatoid arthritis[J]. Drugs, 2013, 73(1): 75-97.
  • 6Chovel-Sella A, Karplus K, Sella T, et al. Clinical efficacy and adverse effects of golimumab in the treatment of rheumatoid arthritis[J], Isr Med Assoc J, 2012, 14(6): 390-394.
  • 7Voulgari P V, Kaltsonoudis E, Papagoras C, et al. Adalimumab in the treatment of rheumatoid arthritis[J]. Expert Opin Biol Ther, 2012, 12(12): 1679-1686.
  • 8Escudero-Vilaplana V, Ramirez-Herraiz E, Trovato-Lopez N, et al. Influence on effectiveness of early treatment with anti-TNF therapy in rheumatoid arthritis [J]. J Pharm Pharm Sci, 2012, 15(3): 355-360.
  • 9Meugnier E, Coury F, Tebib J, et al. Gene expression profiling in peripheral blood ceils of patients with rheumatoid arthritis in response to and-TNF-alpha treatments [J]. Physiol Genomics, 2011, 43(7): 365-371.
  • 10You S, Cho C S, Lee I, et al. A systems approach to rheumatoid arthritis [J]. PLoS One, 2012, 7(12): e51508.

引证文献3

二级引证文献6

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部